Número de publicaciones
576
Buscador de publicaciones
  • Diaz-Gomez, J; Twyman, RM; Zhu, CF; Farre, G; Serrano, JCE; Portero-Otin, M; Muñoz, P.; Sandmann, G; Capell, T; Christou, P

    Biofortification of crops with nutrients: factors affecting utilization and storage

    Current Opinion In Biotechnology 44 115-123. .

    [doi:10.1016/j.copbio.2016.12.002]

  • Cabezon, M.; Bargay, J.; Xicoy, B.; Garcia, O.; Tormo, M.; Palomo, L.; Marce, S.; Valcarcel, D.; Pedro, C.; Jimenez, M. J.; Borras, J.; Guardia, R.; Brunet, S.; Marti, J. M.; Garcia, A.; Zamora, L.

    TP53 MUTATIONS IN HIGH RISK MYELODYSPLASTIC SYNDROMES PATIENTS TREATED WITH AZACITIDINE ACCORDING TO CETLAM GROUP PROTOCOL

    LEUKEMIA RESEARCH 55 155-155. .

    [doi:10.1016/S0145-2126(17)30383-1]

  • Gasol Cudos, A.; Morales Murillo, S.; Panades Siurana, M. J.; Vilardell Villellas, F.; Canosa Morales, C.; Mele Olive, J.; Iglesias Martinez, E.; Salud Salvia, A.

    Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution

    BREAST 32 92-93. .

  • Negredo, E; Estrada, V; Domingo, P; Gutierrez, MD; Mateo, GM; Puig, J; Bonjoch, A; Ornelas, A; Echeverria, P; Estany, C; Toro, J; Clotet, B

    Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals

    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 72 844-849. .

    [doi:10.1093/jac/dkw504]

  • Saumoy, M; Tiraboschi, JM; Ordoñez-Llanos J; Ribera, E; Domingo, P; Mallolas, J; Curto, J; Gatell, JM; Podzamczer, D

    Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy

    HIV CLINICAL TRIALS 18 49-53. .

    [doi:10.1080/15284336.2016.1275425]

  • Arroyo D; Betriu A; Valls J; Gorriz JL; Pallares V; Abajo M; Gracia M; Valdivielso JM; Fernandez E

    Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study

    NEPHROLOGY DIALYSIS TRANSPLANTATION 32 513-520. .

    [doi:10.1093/ndt/gfw039]

  • Carlos Yebenes, Juan; Carlos Ruiz-Rodriguez, Juan; Ferrer, R; Cleries, M; Bosch, A; Lorencio, C; Rodriguez, A; Nuvials, X; Martin-Loeches, I; Artigas, A; SOCMIC Catalonian Critical Care

    Epidemiology of sepsis in Catalonia: analysis of incidence and outcomes in a European setting

    Annals of Intensive Care 7 19-19. .

    [doi:10.1186/s13613-017-0241-1]

  • Cabre, R; Naudi, A; Dominguez-Gonzalez, M; Ayala, V; Jove, M; Mota-Martorell, N; Piñol-Ripoll G; Gil-Villar, MP; Rue, M; Portero-Otin, M; Ferrer, I; Pamplona, R

    Sixty years old is the breakpoint of human frontal cortex aging

    FREE RADICAL BIOLOGY AND MEDICINE 103 14-22. .

    [doi:10.1016/j.freeradbiomed.2016.12.010]

  • Rivero, A; Perez-Molina, JA; Blasco, AJ; Arribas, JR; Crespo, M; Domingo, P; Estrada, V; Iribarren, JA; Knobel, H; Lazaro, P; Lopez-Aldeguer, J; Lozano, F; Moreno, S; Palacios, R; Pineda, JA; Pulido, F; Rubio, R; de la Torre, J; Tuset, M; Gatell, JM

    Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA 35 88-99. .

    [doi:10.1016/j.eimc.2016.06.013]

  • Català Tella N; Serna Arnaiz C; Real Gatius J; Yuguero Torres O; Galván Santiago L

    Assessment of the length of sick leave in patients with ischemic heart disease

    BMC CARDIOVASCULAR DISORDERS 17 32-32. .

    [doi:10.1186/s12872-016-0460-7]

  • Domingo, P; Espinet, J; Vidal, F

    ART regimes and fat: the healing hand wielding the sword

    Lancet HIV 4 2-3. .

    [doi:10.1016/S2352-3018(16)30185-0]

  • Antoni Schoenenberger-Arnaiz, Joan; Solanilla-Puertolas, M; Acer-Puig, M; Gomez-Arbones, J

    Informing primary care physicians of patients' involvement in clinical trials carried out at a specialist care level

    Open Access Journal Of Clinical Trials 9 59-64. .

    [doi:10.2147/OAJCT.S134555]